Reports & Studies
Whether you need brief market studies, surveys, detailed market reports, or market research on a particular topic, we will provide you with the appropriate searches and results.
Fields of Expertise:
- Biotechnology/Life Sciences
- Medicine and Veterinary Medicine
Market reports
Multiplexed Diagnostics (published by Select BioSciences in May 2010)
The multiplexed diagnostics market has grown rapidly and generated sales of approximately $2.4 billon in 2009, but is now balanced on multiple tipping points. Will the FDA finally release the updated IVDMIA guidelines? If so, will the FDA close the CLIA loophole and/or will the FDA require 510(k) approvals for all multivariate diagnostics? Will Genomic Health and Agendia be able to maintain high prices for their flagship tests amidst growing competition? How many new tests will reach the market in 2010? Does the inability of Genomic Health's new colon cancer diagnostic to predict response to chemotherapy indicate ongoing challenges in developing new multivariate diagnostics or is this an isolated example? Will growing competition lead to market confusion?
In situations with similar tests, how will physicians and payers decide? Will they want to see more prospective clinical trials? Will prospective clinical trials be more attractive due to the experience of XDx? As multiplexed diagnostics become more established, will physicians and payers begin to actively seek these new tests to increase the efficiency of healthcare? Will changes in healthcare policies, especially in the US, be a net positive because of the expanded use of tests (for aging and expanding populations) or a net negative because of cost controls? Will new multiplexing technologies, such as MagPix from Luminex and BeadXpress from Illumina, create another shift in the market or are diagnostics laboratories becoming entrenched with current methods? Will new biomarkers, such as microRNA and methylated DNA, be more powerful than gene expression levels? For genetic tests, how far will multiplexing go? Is Counsyl's combination of 100 genetic tests only the beginning? If so, will the increasing complexity of genetic tests usher in the era of diagnostic DNA sequencing?
On the whole, the multiplexed diagnostics market is expected to tip in favor of continued rapid growth, reaching almost $5.8 billion in 2015, according to a new report, Multiplexed Diagnostics 2010, published by Select Biosciences and written by BioPerspectives and Bachmann Consulting. This report explains the unmet needs, trends, regulations, reimbursement, competition, technologies and business strategies. This 572-page report includes a survey of more than 400 respondents, interviews with 12 experts, a detailed database of more than 190 commercial multiplexed diagnostics and a two-tiered quantitative worldwide market model. In addition, the report comes with one hour of consulting (in the form of a conference call) with one of the authors, Dr. Steven Bodovitz, Principal of BioPerspectives, or Dr. Jutta Bachmann, CEO of Bachmann Consulting.
Further information at: www.selectbiosciences.com/marketreports/Multiplexed_Diagnostics_2010.aspx
Next-Generation Immunoassays: A Market and Technical Analysis of Research Applications (publication date: November 2007)
The immunoassay assay is undergoing a major makeover. New amplification methods offer the promise to peer deeper into the proteome; new detection methods offer the promise to see clearer; new multiplexing to look faster and more efficiently; and new content to observe farther. These new technologies are addressing significant unmet needs in sensitivity, accuracy, speed, cost and breadth, according to a new report from BioPerspectives and Bachmann Consulting.
The new report, “Next-Generation Immunoassays: A Market and Technical Analysis of Research Applications,” details the opportunities and challenges in a market valued at more than $1.1 billion in 2003 and projected to grow to more than $2.2 billion in 2012. The report is based on surveys of researchers and thorough evaluations of more than 70 technologies encompassing novel antibody generation, real-time detection, new amplification methods and multiplexed antibody arrays. The financial projections are based on a 3 by 5 market matrix model encompassing instruments, antibodies and other reagents and consumables across ELISAs, Western blots, immunoprecipitations, antibody arrays and novel antibody characterization methods.
In addition, the report comes with an hour of discussion (pending availability and limited to a conference call format) with Steven Bodovitz, Principal of BioPerspectives, or Jutta Bachmann, CEO of Bachmann Consulting. For more information, please visit www.bioperspectives.com or www.jbachmann-consulting.com.
Protein Biochips: Parallelized Screening for High-Output Biology (Published August 2004 by BioPerspectives and Bachmann Consulting)
The protein biochip industry is shedding hype and demonstrating real value. The grandiose visions of technologies to study the entire human proteome are giving way to pragmatic divide-and-conquer approaches. This transition is driving the projected growth in the market from $122 million in 2002 to more than $500 million in 2008, according to this new report written by an international team of experts. The comprehensive, 269-page report has unparalleled analysis and coverage of the protein biochip market, including both planar and bead arrays. The report features a detailed discussion of the key drivers and a 3 X 2 X 2 X 2 hierarchical market model. In addition, the report features detailed evaluations of the technologies and business strategies of 61 companies. Furthermore, to enable readers to take full advantage of the expertise of the authors, the report comes with one free hour of consulting.